Aragão Gomes, Luis
Uytterhoeven, Valerie http://orcid.org/0000-0003-3100-2079
Lopez-Sanmartin, Diego
Tomé, Sandra O.
Tousseyn, Thomas
Vandenberghe, Rik http://orcid.org/0000-0001-6237-2502
Vandenbulcke, Mathieu
von Arnim, Christine A. F. http://orcid.org/0000-0002-8614-2223
Verstreken, Patrik
Thal, Dietmar Rudolf http://orcid.org/0000-0002-1036-1075
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G0F8516N)
Vlaamse Overheid (IWT 135043)
Article History
Received: 4 September 2020
Revised: 26 November 2020
Accepted: 29 November 2020
First Online: 11 January 2021
Compliance with ethical standards
:
: DLS is currently an employee of Novartis Oncology Spain. CAFvA received honoraria from serving on the scientific advisory board of Roche (2018–2019) and Dr. Willmar Schwabe GmbH & Co. KG (2019) and has received funding for travel and Speaker honoraria from Nutricia GmbH (2014–2015), Lilly Deutschland GmbH (2013–2016), Biogen (2016–2018), Roche (2017–2019) and Dr. Willmar Schwabe GmbH & Co. KG (2014–2015). RV was PI of the first-in-human trial with 18F-MK6240 (Merck) and global PI of the phase 1 and 2 trials of 18F-flutemetamol (GE). RV’s institution has consultancy agreements (RV as consultant) with Novartis and AC-Immune as well as clinical trial agreements (RV as PI) with AbbVie, Roche, Prevail and Alector. DRT received speaker honorary from Novartis Pharma AG (Switzerland), Biogen (USA), travel reimbursement from GE-Healthcare (UK) and UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium).